<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00298714</url>
  </required_header>
  <id_info>
    <org_study_id>ARAHEPC</org_study_id>
    <secondary_id>Protocol number: 02-0491</secondary_id>
    <nct_id>NCT00298714</nct_id>
  </id_info>
  <brief_title>Effects of Losartan on Hepatic Fibrogenesis in Chronic Hepatitis C</brief_title>
  <official_title>Effect of Long-Term Administration of Oral Losartan on Hepatic Fibrogenesis and Gene Expression in Chronic Hepatitis C With Significant Liver Fibrosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <brief_summary>
    <textblock>
      There is evidence on the beneficial effects of the administration of angiotensin II type 1
      (AT1) receptors antagonists on liver fibrosis in hepatic stellate cells, experimental models
      of liver fibrosis in rodents and limited information in chronic hepatitis C with mild
      fibrosis.

      The purpose of this study is to investigate the effect of long-term administration of oral
      Losartan, an AT1 receptor antagonist, on liver fibrogenesis in patients with chronic
      hepatitis C and fibrosis F2-F3 (METAVIR score).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of liver fibrogenesis by changes in gene expression of key mediators of liver fibrosis.</measure>
  </primary_outcome>
  <enrollment>20</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <condition>Liver Fibrosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age between 35 and 65 years

          -  chronic hepatitis C with intermediate fibrosis (F2-F3 in Metavir score).

          -  non-responder or contraindication to antiviral therapy.

        Exclusion Criteria:

          -  any other cause of liver disease

          -  HIV positive

          -  alcohol consumption

          -  arterial hypertension

          -  creatinine &gt; 1.5mg/dL

          -  treatment with AT1 receptor antagonists or angiotensin converting enzyme inhibitors in
             the past 12 months.

          -  antiviral therapy in the past 12 months

          -  contraindications to oral losartan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pere Ginès, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liver Unit, Institut Clínic de Malalties Digestives, Hospital Clínic, Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vicente Arroyo, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Liver Unit, Institut Clínic de Malalties Digestives, Hospital Clínic, Barcelona</affiliation>
  </overall_official>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2006</study_first_submitted>
  <study_first_submitted_qc>March 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2006</study_first_posted>
  <last_update_submitted>November 21, 2007</last_update_submitted>
  <last_update_submitted_qc>November 21, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2007</last_update_posted>
  <keyword>Hepatitis C, Chronic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

